First month prednisone dose predicts prednisone burden during the following 11 months: An observational study from the RELES cohort

Lupus Science and Medicine

Volumn 3, Issue 1, 2016, Pages

  Ruiz Irastorza, G ^a   Garcia, M ^a   Espinosa, G ^b   Caminal, L ^c   Mitjavila, F ^d   Gonzalez Leon R ^e   Sopena B ^f   Canora, J ^g   Villalba, M V ^h   Rodriguez Carballeira M ^d   Lopez Dupla J M ⁱ   Callejas, J L ^j   Castro, A ^k   Tolosa, C ^l   Sanchez Garcia M E ^m   Perez Conesa M ⁿ   Navarrete Navarrete, N ^o   Rodriguez A P ^p   Herranz, M T ^q   Pallares L ^r  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^g HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

ⁱ HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^j HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^k HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^l Servicio de Oncología Médica   (Spain)

^m HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

ⁿ HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^o HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^p Hospital Universitario Virgen de Las Nieves ^*  (Spain)

^q HOSPITAL MORALES MESEGUER   (Spain)

^r HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

more..

Author keywords

Corticosteroids; Disease Activity; Systemic Lupus Erythematosus

Indexed keywords

DNA ANTIBODY; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PREDNISONE;

ADULT; AGED; ARTICLE; AVASCULAR NECROSIS; COHORT ANALYSIS; CRUSH TRAUMA; DRUG MEGADOSE; DRUG PULSE THERAPY; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NEPHRITIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SIDE EFFECT; SLEDAI; SPINE FRACTURE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; YOUNG ADULT;

EID: 84981156261     PISSN: None     EISSN: 20538790     Source Type: Journal    
DOI: 10.1136/lupus-2016-000153     Document Type: Article

References (14)

1. Zonana-Nacach A, Barr SG, Magder LS, et al. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000;43:1801-8.
2. Bruce IN, O'Keeffe AG, Farewell V, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis 2015;74: 1706-13.
3. Ruiz-Irastorza G, Garcia M, Espinosa G, et al. Patterns of drug therapy in newly diagnosed Spanish patients with systemic lupus erythematosus. Clin Exp Rheumatol 2016;34:466-72.
4. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
5. Buttgereit F, Straub RH, Wehling M, et al. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum 2004;50:3408-17.
6. Ruiz-Arruza I, Ugarte A, Cabezas-Rodriguez I, et al. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2014;53:1470-6.
7. Alarcón GS, Friedman AW, Straaton KV, et al. Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. LUpus in MInority populations: NAture vs. Nurture. Lupus 1999;8:197-209.
8. Parker B, Urowitz MB, Gladman DD, et al. Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis 2015;74:1530-6.
9. van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 2014;73:958-67.
10. Ruiz-Irastorza G, Danza A, Perales I, et al. Prednisone in lupus nephritis: how much is enough? Autoimmun Rev 2014;13:206-14.
11. Fischer-Betz R, Chehab G, Sander O, et al. Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: a prospective observational study. J Rheumatol 2012;39:2111-17.
12. Zeher M, Doria A, Lan J, et al. Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus 2011;20:1484-93.
13. Ruiz-Arruza I, Barbosa C, Ugarte A, et al. Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis. Autoimmun Rev 2015;14:875-9.
14. Parker BJ, Bruce IN. High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus. Lupus 2007;16:387-93.